Overview

Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Evaluation of the aqueous concentrations of 2 topical NSAIDS as well as the PGE2 inhibition in human patients.
Phase:
Phase 4
Details
Lead Sponsor:
Innovative Medical
Treatments:
Bromfenac
Ketorolac
Ketorolac Tromethamine